

**Table 1. Sequence of Primers sequences used in this study were as follows:**

Name	Primer sequence (5'→3')
hsa_circ_0004893(F)	GTTGCAGGATTGGGAAGGTT
hsa_circ_0004893(R)	CAGTCTCGGTGTCCAGGAGT
hsa_circ_0002970(F)	AGACGAAAGGGGAGGTTATGA
hsa_circ_0002970(R)	TGCAGGTACATTGGTTTCCC
hsa_circ_0008199(F)	AGAATAAAGATAACCAAGACAAGAG
hsa_circ_0008199(R)	TTGCGAAGACACCTGAAGC
hsa_circ_0045462(circ-BPTF) (F)	CCTGTGATGGTACAGCCAGAAA
hsa_circ_0045462(circ-BPTF) (R)	TGGTGCTGGTTGTACTIONGCTTGT
Negative control siRNA (NC-siRNA) (F)	UUCUCCGAACGUGUCACGUTT
Negative control siRNA (NC-siRNA) (R)	ACGUGACACGUUCGGAGAATT
Negative control mimics (NC-mimics) (F)	UUCUCCGAACGUGUCACGUTT
Negative control mimics (NC-mimics) (R)	ACGUGACACGUUCGGAGAATT
miR-486-5p sense	GATGCACATCCTGTACTGAGCTG
miR-486-5p antisense	TATGGTTGTTACGACTCCTTCAC
<i>U6</i> sense	CTCGCTTCGGCAGCACA
<i>U6</i> antisense	CTCGCTTCGGCAGCACA
<i>CEMIP</i> sense	CCAGGAATGTTGAATGTCT
<i>CEMIP</i> antisense	ATTGGCTCTTGGTGAATG
<i>GAPDH</i> (F)	AATCCCATCACCATCTTC
<i>GAPDH</i> (R)	AGGCTGTTGTCATACTTC

**Table 2. Baseline characteristics of all patients**

	COPD (n=18)	non-COPD (n=13)	<i>P</i> value
M/F (n)	13/5	9/4	0.85
Age (years)	64.20±9.82	57.07±12.18	0.09
Smoker (n)	4	2	0.65
FEV1/pred (%)	73.65±11.59	94.87±11.13	<0.01
FEV1/FVC (%)	60.52±8.75	79.13±7.04	<0.01
PaO <sub>2</sub> (mmHg)	69.3±6.2	82.6±5.2	<0.01